[Juvenile dermatomyositis-what's new?]

Area of Science:

• Pediatric Rheumatology
• Immunology
• Dermatology

Background:

• Juvenile dermatomyositis (JDM) is the most common chronic inflammatory myopathy in children, often presenting with a complicated disease course.
• Understanding the pathogenesis and clinical manifestations of JDM is crucial for improving patient outcomes.

Purpose of the Study:

• To review novel findings related to Juvenile Dermatomyositis (JDM).
• To discuss the role of myositis-specific antibodies and type I interferon pathways in JDM pathogenesis and clinical presentation.
• To outline current and potential future therapeutic strategies for JDM.

Main Methods:

• Literature review of recent findings in Juvenile Dermatomyositis.
• Analysis of the role of myositis-specific antibodies and interferon pathways.
• Evaluation of current treatment standards and emerging therapeutic options.

Main Results:

• Myositis-specific antibodies are frequently detected and may correlate with JDM phenotypes and disease course.
• Type I interferon pathway activation is pathogenically important and linked to clinical manifestations.
• Current standard therapy includes glucocorticoids and methotrexate; refractory cases may use other immunosuppressants.

Conclusions:

• Novel insights into JDM pathogenesis, including antibodies and interferon pathways, may lead to targeted therapies.
• Optimal JDM treatment is not yet established, but consensus recommendations and validated assessment tools can guide management.
• The PRO-KIND initiative offers a diagnostic and treat-to-target strategy for JDM.